(S)-3-(tert-Butoxycarbonyl)thiazolidine-2-carboxylic acid, 95.0%, 100mg

ethyl 5-oxo-1-(propan-2-yl)-2,5-dihydro-1H-pyrazole-3-carboxylate, 95+%, 2g

6-Chloro-3-(4-chlorophenyl)-[1,2,4]triazolo[4,3-b]pyridazine, 95%, 1g

1,10-Dichlorodecane, 95.0%, 25g

Chlorure de strontium hexahydraté, min 99 %, pa, 100 g, emballage plastique.

Fmoc-D-Gln(Trt)-OH, 96%, 5g

3,5-Dimethoxy-4-hydroxybenzhydrazide, 95%, 500mg

N-(4-(TRIFLUOROMETHYL)PHENYL) FORMAMIDE, 95.0%, 1g

6-(p-Tolyl)pyridin-2-ol, 95.0%, 1g

1-(6-Amino-5-methoxyindolin-1-yl)ethanone, 95.0%, 1g

Pipette microlitre monocanal ROTILABO®, 10 à 100 µl, 1 pièce

2-(3-Fluoro-4-(methylthio)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, 98%, 1g

N-Methyl-N-(trifluoromethylthio)aniline>98.0%(GC)1g